IBM's Watson takes aim at cancer
IBM Research and the New York Genome Center want to prove that IBM's Watson can dramatically reduce the time required to identify the most effective cancer treatments based on an analysis of a specific patient's genetic mutations. In partnership with regional hospitals, the NYGC plans to evaluate Watson's ability to help oncologists develop more personalized care for patients with glioblastoma, an aggressive and malignant brain cancer that kills more than 13,000 people in the US each year. The NYGC is a nonprofit consortium of the state's academic, medical, and university leaders working to advance the applications of genomics, the branch of genetics that studies complete DNA sequences rather than individual genes.
- Interventional Radiology No Longer a Sub-Specialty
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Acute Kidney Injury Gets New Focus
- Transforming Cancer Care
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- mHealth Tackles Readmissions
- Evidence-Based Practice and Nursing Research: Avoiding Confusion
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Sharp HealthCare Leaves Pioneer ACO Program
- MA an Insurance Proving Ground for Providers